
    
      Secondary Objectives in this trial include the following:

        -  To estimate the survival of study recipients at one year after infusion of the T- and
           B-lymphocyte depleted stem cell graft.

        -  To assess if the study treatment enables the recipient to generate normal donor-derived
           B-cell numbers and endogenous IgM, IgG, and IgA production, resulting in a
           reduction/elimination of the need for intravenous immunoglobulin infusions.

        -  To determine if the study treatment results in the ability of the research participant
           to generate normal donor-derived T cell response and natural killer (NK) cell numbers
           and function.

        -  To describe the incidence of Epstein-Barr virus-lymphoproliferative disease (EBV-LPD) in
           these transplant recipients.
    
  